Research
Hormonal
Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.
If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.
GoodSupportsHIGH confidence
It restores the impaired MC4R pathway caused by deficiencies in upstream genes such as POMC, PCSK1, or LEPR. Consequently, it reduces hunger, promotes metabolism, and aids in weight reduction for patients suffering from MC4R pathway deficiencies.
Why this rating
The paper cites FDA approval and established clinical efficacy for this specific indication.
Source
A Complex Network of Obesity‐Risk Genes Revealed by Systematic Bioinformatics and Single‐Cell Transcriptomic Analyses
Y. Liu et al. · Journal of Obesity · 2025
DOI 10.1155/jobe/7821115
mechanism_onlyCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity pathogenesis is driven by a complex network of 802 core genetic risk genes that function through integrated neurological (appetite regulation, synaptic signaling) and metabolic (lipid/glucose homeostasis) pathways.Moderate
- Obesity-risk genes are highly expressed in specific cell types: hypothalamic neurons (regulating appetite), pancreatic beta-cells (regulating insulin), adipocytes (lipid homeostasis), and hepatocytes (lipid metabolism).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →